CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 155 enrolled
Drug / intervention
Dasatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02689440
NCT02689440Phase 2Active
CompareCT.gov

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Venetoclax: A Phase II Study

M.D. Anderson Cancer Center·interventional·Posted Feb 24, 2016·Updated Mar 5, 2026

In Brief

A Phase 2 clinical trial evaluating Dasatinib, Laboratory Biomarker Analysis, and 1 other intervention for Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia. Active but no longer recruiting, targeting 155 participants across 1 site.

Detailed Summary

This phase II trial studies how well dasatinib and venetoclax work in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia. Dasatinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2Active
20162017201820192020202120222023202420252026202720282029203020312032203320342035203620372038203920402041
First PostedFeb 24, 2016
Enrollment StartFeb 19, 2016
Primary CompletionDec 31, 2040
TodayJul 1, 2026
Enrollment to primary: 24.9 yearsPosted 10.4 years agoPrimary completion in 14.5 years

Interventions

Dasatinibdrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies

Venetoclaxdrug

Given PO